Myeloproliferative Neoplasms News

Pawel Muranski, MD, has been joined NewYork-Presbyterian and Columbia University Medical Center as director of cellular immunotherapy at the newly established Good Manufacturing Practices cell production lab and assistant director of transfusion medicine and cellular therapy.

Mike Schmidt, a former member of the Philadelphia Phillies widely considered to be the greatest third baseman in Major League Baseball history, received a stage III melanoma diagnosis in 2013.

Mike Schmidt is widely considered the greatest third baseman in Major League Baseball history.

Mike Schmidt always felt a sense of invincibility as a professional athlete.

Basic research in immunotherapy and precision medicine remains at the forefront of progress in cancer treatment; however, a strong bipartisan commitment from Congress is needed to continue this progress, according to the seventh annual AACR Cancer Progress Report.

The FDA placed a partial clinical hold on five trials and a full clinical hold on one trial, all designed to evaluate durvalumab in combination with immunomodulatory and chemotherapy agents for the treatment of hematologic malignancies.

ASH selected 20 hematology trainees and early career faculty members to participate in the ASH Clinical Research Training Institute.

The FDA placed a clinical hold on two phase 1 trials designed to evaluate UCART123 for the treatment of patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.

Jazz Pharmaceuticals and ImmunoGen entered into a strategic collaboration and option agreement to develop and commercialize two antibody-drug conjugates.

ASH will honor several distinguished leaders in hematology at its annual meeting in December.